Significance Statement {#s1}
======================

A substantial literature provides a detailed description of the postsynaptic mechanisms underlying memory-related long-term potentiation (LTP) in hippocampal field CA1 and elsewhere in the cortical telencephalon. The present article introduces a different, presynaptic form of LTP localized to one of the two principal cortical inputs to hippocampus, the lateral perforant path. This projection conveys information used in the generation of episodic memory, a key element of human cognition. Intriguingly, an endocannabinoid serves as the retrograde (postsynaptic-to-presynaptic) messenger that is required for the induction of the novel plasticity effect, an observation possibly related to the influence of cannabinoid drugs on orderly thought. Finally, it is proposed that the regionally restricted version of plasticity described here enables differential encoding between hippocampal inputs.

Introduction {#s2}
============

Marijuana alters human cognition in profound and complex ways ([@B105]; [@B38]). This effect is thought to reflect the interaction of its main psychoactive constituent, Δ^9^-tetrahydrocannabinol, with a modulatory system present in the brain that includes two lipid-derived neurotransmitters---2-arachidonoyl-*sn*-glycerol (2-AG) and anandamide---and their attending G-protein-coupled cannabinoid receptors ([@B12]). 2-AG, the most abundant of these endocannabinoids ([@B86]), is produced through the activation of metabotropic glutamate 5 receptor (mGluR5) in dendritic spines ([@B45]; [@B42]) at excitatory synapses throughout the CNS. By contrast, CB~1~ cannabinoid receptors, which mediate the majority of the synaptic actions of 2-AG, are concentrated in axon terminals ([@B45]; [@B107]; [@B12]). This morphological segregation, along with the ability of CB~1~ to depress calcium channel activity and neurotransmitter release, has led to broad acceptance of the idea that spine-derived 2-AG provides a retrograde signal that modulates release during heightened postsynaptic activity ([@B44]).

A local mechanism for transiently adjusting the strength of excitatory and inhibitory transmission would be expected to have potent effects on learning-related synaptic plasticity. In accord with this, there is a sizable literature showing that manipulating endocannabinoid signaling affects the induction of hippocampal long-term potentiation (LTP), but with conflicting results: several studies describe positive effects on potentiation (for discussion, see[@B11]; [@B60]); while others found a negative influence (for review, see [@B6]; [@B103]).

The present studies began with questions of whether and how endocannabinoids contribute to the production of LTP in the lateral perforant path (LPP), one of two cortical inputs to hippocampus ([@B111]; [@B10]; [@B112]; [@B108]; [@B2]). Mechanisms at this connection are of particular interest as recent work has linked the LPP to the formation of episodic memory in rodents ([@B110]) and humans ([@B88]), and thus to a fundamental component of cognition. Related to this, past work established that LPP-LTP is NMDA receptor (NMDAR) dependent ([@B32]) and is strongly modulated by local opioids ([@B9]; [@B23]). However, it is not known whether LTP in this system involves the same cellular mechanisms for stabilization and expression of the potentiated state that have been described in detail for Schaffer-commissural (S-C) afferents of field CA1 ([@B63]; [@B29]). The present results demonstrate that the substrates for LPP potentiation are indeed different than at other sites in hippocampus. Data obtained with a broad array of manipulations support the conclusion that the endocannabinoid 2-AG, acting on presynaptic CB~1~ receptors during brief bursts of high-frequency afferent stimulation, elicits a lasting increase in the evoked release of glutamate from LPP terminals. This 2-AG-dependent LTP was unaffected by the suppression of GABAergic transmission and was not detected at other sites in hippocampus. In all, the results describe an unusual, pathway-specific form of LTP that may be critically involved in the production of orderly thought.

Materials and Methods {#s3}
=====================

All studies were conducted using adult rats and mice, as detailed below, and in accordance with the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* and institutionally approved protocols.

Hippocampal slices and extracellular field recordings {#s3A}
-----------------------------------------------------

Studies used 5- to 8-week-old male rats (Sprague Dawley) and mice, including transgenic mice overexpressing monoacylglycerol lipase (MGL; [@B43]) or lacking expression of the CB~1~ receptor ([@B21]); mice with genetic manipulations were evaluated in comparison with background strain-matched wild-type (WT) mice (2--3 months old, male). Acute hippocampal slices maintained in an ACSF bath in an interface recording chamber were used for electrophysiological extracellular field potential analyses. For slice preparation, animals were killed by decapitation under deep isoflurane anesthesia, and the brain was quickly submerged into oxygenated, ice-cold, high-magnesium ACSF containing the following (in m[m]{.smallcaps}): 124 NaCl, 3 KCl, 1.25 KH~2~PO~4~, 5 MgSO~4~, 26 NaHC0~3~, and 10 dextrose. Using a McIlwain tissue chopper for rat and a Leica vibrating tissue slicer (Model VT1000S) for mouse, slices from the middle third of the hippocampal septotemporal axis were sectioned at a thickness of 330--400 µm, collected into oxygenated, high-magnesium ACSF, and then were transferred into an interface recording chamber (32 ± 1°C, 95% O~2/~5% CO~2~) and continuously perfused with preheated oxygenated ACSF containing the following (in m[m]{.smallcaps}): 124 NaCl, 3 KCl, 1.25 KH~2~PO~4~, 1.5 MgSO~4~, 26 NaHCO~3~, 2.5 CaCl~2~, and 10 dextrose at a rate of 60-70 ml/h. Experiments were initiated ∼1.5 h after slices were placed in the recording chamber.

Field EPSPs (fEPSPs) for the LPP, medial perforant path (MPP), and field CA1 S-C systems were elicited using bipolar stimulating electrodes (65 µm twisted nichrome wire) and recorded with a glass recording electrode (2 [m]{.smallcaps} NaCl filled; 2--3 MΩ; [@B106]). Switching the anode from one pole to the other of the bipolar stimulation electrode substantially changes the magnitude of the elicited fEPSP, indicating minimal spread of current from the active tip (48.6 ± 8.1%, *n* = 6; *p* \< 0.003, paired *t* test). To verify placement in the LPP versus MPP system, evoked responses were initially tested with paired-pulse stimuli (40 and 200 ms interpulse intervals). LPP responses show paired-pulse facilitation, and MPP responses show paired-pulse depression ([@B15]). Stable baseline recordings of responses to low-frequency stimulation (single pulses delivered at 0.05 Hz with stimulation intensity was adjusted to 50--60% of the maximum spike-free fEPSP) were collected for at least 20 min prior to pharmacological manipulation or the induction of LTP, which entailed the following: (1) for the LPP, two 100 Hz trains, each lasting 1 s and separated by 1 min with stimulus duration and intensity at 2× and 1.5× baseline levels, respectively; (2) for the MPP, three 100 Hz trains, 500 ms each, and separated by 50 s, delivered at twice the duration of baseline stimulation and in the presence of picrotoxin (PTX; [@B32]); and (3) for S-C projections, a single train of 10 theta bursts (TBS: 100 Hz bursts of four pulses, separated by 200 ms, delivered at baseline stimulus intensity; [@B58]).

Initial fEPSP slopes and amplitudes were measured from digitized traces (NACGather 2.0, Theta Burst Corp.) and normalized to mean responses over the last 5 min of the baseline period. Plots of electrophysiological measures (fEPSPs and whole-cell recordings) show group mean ± SEM values. The magnitude of LTP was assessed by measures of fEPSP slope for the 5 min period from 55 to 60 min after inducing stimulation, relative to mean responses during the last 5 min of baseline recordings, unless otherwise noted. Paired-pulse facilitation (PPF; i.e., the percentage increase in the second evoked response relative to the first in the pair) was assessed using a 40 ms interval between pulses. Slices in which the initial PPF, during the baseline period, was \>75% (8.5% of cases) were not included in the analysis. For all electrophysiological studies, *N* values given in captions are for the total number of slices from at least three animals per group.

For hippocampal slice field recording studies, compounds were introduced to the ACSF bath (6 ml/h) via an independent perfusion line using a syringe pump; the period of infusion is indicated with a horizontal gray line in figures. The following reagents and treatment concentrations were used: NMDAR antagonist [dl]{.smallcaps}-APV sodium salt (100 µ[m]{.smallcaps}), latrunculin A (Lat-A; 500 n[m]{.smallcaps}), and CB~1~ antagonist SR141716A (5 µ[m]{.smallcaps} for field and 25 µ[m]{.smallcaps} for whole-cell experiments; all from Tocris Bioscience); CB~1~ agonist WIN55,212-2 (WIN) mesylate (5 µ[m]{.smallcaps}), CB~1~ inverse agonist AM251 (5 µ[m]{.smallcaps}), and tetrahydrolipstatin (THL; 10 µ[m;]{.smallcaps} Orlistat; all from R&D Systems); JZL184 (1 µ[m]{.smallcaps}; from RTI International); PTX (5--100 µ[m]{.smallcaps} as noted; from Sigma-Aldrich), URB597 (1 µ[m]{.smallcaps}; from Italian Institute of Technology), WWL70 (10 µ[m]{.smallcaps}; from Cayman Chemical), and 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP; 40 µ[m]{.smallcaps}; donated by the FRAXA Research Foundation). MPEP, AP5, and (*RS*)-3,5-dihydrophenylglycine were dissolved in water. Other compounds were dissolved in 100% dimethylsulfoxide (DMSO) or ethanol and diluted in ACSF to a final concentration of ≤0.1% diluent in the ACSF bath; the one exception was WWL70, for which the final bath DMSO concentration was 0.5%. The effects of AM251, SR141716A, WIN55,121-2, JZL184, URB597, and MPEP generated the same results with and without PTX in the ACSF bath.

Past experience indicates that consistency across experiments is best achieved by having a single investigator conduct all phases of a given slice study. It is very difficult to fully blind such experiments, but a number of steps were taken to avoid bias. These included between-group comparisons of the following pretreatment measures: stimulation currents; waveforms of synaptic potentials; input/output curves; and paired-pulse facilitation. There was detailed analysis of the raw data along with each stage of its processing by a second investigator. Moreover, the effects of experimental treatments were tested on slices from the same animal evaluated in parallel on separate chambers, and a number of points were tested by two researchers. In the case of mutants, it was possible to test groups blindly when differences in physical characteristics or behavior, or markers for gene cohort, were absent.

Whole-cell recordings {#s3B}
---------------------

Hippocampal slices were prepared on the horizontal plane at a thickness of 370 µm from 3- to 4-week-old rats with a Leica vibrating tissue slicer. Slices were placed in a submerged recording chamber and continuously perfused at 2--3 ml/min with oxygenated (95% O~2~/5% CO~2~) at 32°C. Whole-cell recordings (Axopatch 200A amplifier; Molecular Devices) were made with 4--7 MΩ recording pipettes filled with a solution containing (in m[m]{.smallcaps}): 130 CsMeSO~4~, 10 CsCl, 8 NaCl, 10 HEPES, 0.2 EGTA, 5 QX-314, Mg-ATP, and 0.3 Na-GTP. Osmolarity was adjusted to 290--295 mOsm and pH buffered at 7.25. Bipolar stimulating electrodes were placed in the outer molecular layer to stimulate the LPP. EPSCs were recorded by clamping the granule cell at −70 mV in the presence of 50 µ[m]{.smallcaps} PTX ([@B39]). LTP was induced using a pairing protocol of 2 Hz stimulation for 75 s at a holding potential of −10 mV, after recording a stable 10 min baseline. The LPP-mediated PPF was measured before and after LTP induction by the application of paired-pulse stimulation at an interval of 100 ms. To assess the NMDAR- and AMPA receptor (AMPAR)-mediated EPSC ratio, cells were held at +40 mV, and AMPAR-mediated currents isolated with the selective NMDAR antagonist [dl]{.smallcaps}-APV. The NMDAR-mediated currents were then determined by subtracting the AMPAR-mediated currents from the total EPSC. To specifically study postsynaptic effects, 400 n[m]{.smallcaps} latrunculin A or 10 m[m]{.smallcaps} BAPTA was applied postsynaptically via intracellular infusion through the patch pipette applied to individual granule or pyramidal cells.

Lipid quantification and activity assays {#s3C}
----------------------------------------

Levels of 2-AG, oleoylethanolamide (OEA), and stearic acid were determined using published liquid chromatography/mass spectrometry (LC/MS) methods. Immediately after behavioral testing, dentate gyrus (DG) and CA1 fields were dissected and snap frozen, or punches were taken of dentate gyrus and auditory cortex from fast-frozen, cryostat-mounted brains. From methanol homogenates, lipids were extracted with chloroform, and further fractionated by open-bed silica gel column chromatography. The eluates were dried under N~2~ and reconstituted in chloroform/methanol for LC/MS analyses. Measures from both types of sampling were combined after normalization to respective control regions. Activities of fatty acid amide hydrolase (FAAH) and 2-AG-hydrolase MGL were measured using published techniques ([@B50]; [@B73]). Dentate gyrus results were normalized for each animal to values for the auditory cortex or field CA1.

Stochastic optical reconstruction microscopy imaging {#s3D}
----------------------------------------------------

For three-dimensional super-resolution Stochastic optical reconstruction microscopy (STORM) imaging, fresh-frozen brains from young adult 5- to 8-week-old male Sprague Dawley rats were sectioned and processed for dual immunofluorescence using a cocktail of primary antisera, including rabbit anti-CB~1~ ([@B70]) with mouse anti-SYN (MAB5258 clone Sy38, Millipore) or mouse anti-postsynaptic density-95 (PSD-95; MA1-045 clone 6G6-1C9, Thermo Scientific) and secondary antisera conjugated to photoswitchable dyes (Alexa Fluor 647 and Atto 488). Immunolabeling was visualized using a Nikon TIRF microscope equipped with a 100× objective and ANDOR iXon CCD camera; this system supports resolution of individual molecules as close together as 20 nm ([@B20]). Both channels were recorded simultaneously until ≥500,000 molecules were detected, and then Nikon NIS software was used to reconstruct the image free of nonspecific background activation. Using Python 2.7, densely labeled synapses were identified by applying a clustering algorithm ([@B90]) to the field of molecules to filter out elements smaller than seven molecules. Coordinates for the centroid of each cluster were used to calculate distances between elements.

Odor discrimination behavior {#s3E}
----------------------------

All behavioral sessions were video recorded by overhead camera, and behavioral analyses were conducted from the videos by individuals blind to treatment. Well handled male Long--Evans rats (6--10 weeks old) were kept on a reverse 12 h light/dark cycle, maintained at 90% normal body weight, and handled for six sessions, two sessions per day, prior to odor discrimination training ([@B69]). The test apparatus consists of a 15 × 28 × 15 inch white acrylic box, resting on a chromed wire grid with holes cut to accept 2-inch-diameter plastic or glass "digging cups" to hold sand for behavioral testing. For odor discrimination training, rats were trained to distinguish between unique odors presented in pairs, with one odor per pair rewarded. Odorants were finely pulverized household spices, mixed with clean dry sand at a ratio of 1 g of odorant to 100 g of sand (odorants included anise, basil, cinnamon, coffee, cocoa, coriander, cumin, dillweed, fenugreek, ginger, lavender flower, oregano, peppermint, rose petal, rosemary, and sage). Sand cups were filled with the mixture with one cup baited, and the rat was allowed to dig; if the rat chose the wrong cup or did not dig before 30 s, it was removed until the next trial; if it chose the correct cup, it was allowed to consume the half-Froot Loop treat and then removed until the next trial. The intertrial interval was 20--30 s; cups were replaced and positions randomized between trials. Sessions of 10 30 s trials on a given odor pair were repeated up to twice daily until rats reached a success rate of ≥80% correct before the introduction of a new odor pair. Testing of drug effects on learning novel odors commenced on the following day. For AM251 treatments, rats were given an intraperitoneal injection of AM251 (1 mg/kg) or vehicle (veh: DMSO, cremophore, ethanol, 0.9% saline, at 1:1:1:17) 1 h prior to training (10 trials) on a new odor pair. Rats were tested again 24 h later on the same pair of odors. For JZL184 treatments, rats were given an intraperitoneal injection of this compound (16 mg/kg, i.p.) or vehicle (80% polyethylene glycol 200, 20% Tween 80) 6 h prior to six training trials; rats were then killed immediately following training for neurochemical measures or were tested for retention 24 h later on the same odor pair.

Statistics {#s3F}
----------

All results are presented as mean ± SEM values. Statistical significance (*p* \< 0.05) was evaluated using one- or two-tailed Student's *t* test, the nonparametric Mann--Whitney or Wilcoxon signed rank test (for comparison of two groups), and the two-way ANOVA, as indicated (Prism, GraphPad). In graphs, asterisks denote the level of significance (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001).

Results {#s4}
=======

2-AG-dependent LTP in the lateral perforant path {#s4A}
------------------------------------------------

High-frequency stimulation (HFS) of the LPP in acute rat hippocampal slices elicited enduring LTP at LPP synapses with DG granule cells. In studies using field recordings, this potentiation was prevented by bath application of the CB~1~ inverse agonist AM251 (5 µ[m]{.smallcaps}; [Fig. 1A](#F1){ref-type="fig"}). Adding PTX (10 µ[m]{.smallcaps}) to the ACSF perfusate did not measurably affect the magnitude of LPP-LTP in slices treated with veh (without PTX, 59.1 ± 8.6%; with PTX, 62.2 ± 4.1%; *p* \> 0.75, two-tailed *t* test) or with AM251 (*p* \< 0.004, without PTX; *p* \< 0.001, with PTX, two-tailed tests; [Fig. 1A](#F1){ref-type="fig"}). To confirm that endocannabinoids do not promote LPP-LTP via actions on fast inhibitory transmission, we repeated the field recording experiment using the CB~1~ antagonist SR141716A (5 µ[m]{.smallcaps}; [@B49]) applied in the presence of 100 µ[m]{.smallcaps} PTX: LTP was greatly reduced by the antagonist (percentage of LTP: vehicle plus PTX, 70.3 ± 4.9%; SR141716A plus PTX, 28.7 ± 5.0%; *p* = 0.0004, two-tailed *t* test; [Fig. 1B](#F1){ref-type="fig"}). Finally, we evaluated SR141716A effects on LPP potentiation using whole-cell recordings and in the presence of 50 µ[m]{.smallcaps} PTX, conditions in which we could verify that IPSCs were fully eliminated. LPP-LTP was again markedly reduced: percentage of LTP at 25 min postinduction was 97.4 ± 24.9% with vehicle plus PTX and 29.1 ± 10.8% with SR141716A plus PTX present (*p* \< 0.005, two-tailed *t* test; [Fig. 1C](#F1){ref-type="fig"}).

![LPP-LTP is endocannabinoid and CB~1~ dependent. ***A***, The CB~1~ inverse agonist AM251 (5 µ[m]{.smallcaps}, at horizontal bar) disrupts LPP-LTP with or without PTX (10 µ[m]{.smallcaps}) in the ACSF bath. Veh-treated slices included those tested with (+) and without (−) PTX present. Potentiation, assessed 55--60 min after high-frequency stimulation, was greatly reduced in both AM251 groups (*p* \< 0.0004, −PTX; *p* \< 0.001, +PTX; *n* = 5 each) relative to veh. ***B***, Perfusion of the CB~1~ antagonist SR141716A (5 µ[m]{.smallcaps}) in the presence of 100 µ[m]{.smallcaps} PTX significantly attenuated LPP-LTP, as assessed with field recordings (*p* = 0.0004, two-tailed *t* test for percentage of LTP in veh vs SR141716A). ***C***, CB~1~ antagonist SR141716A also significantly reduced the percentage of LPP potentiation as assessed 25 min postinduction using voltage-clamp recordings of granule cells in slices treated with veh (*n* = 8) or 25 µ[m]{.smallcaps} SR141716A (*n* = 6; \*\**p* \< 0.005, two-tailed *t* test vs veh+PTX): traces show EPSCs collected before and 30 min after induction for veh slices. Calibration: 100 pA, 50 ms. ***D***, ***E***, AM251 did not reduce LTP of the MPP (***D***) or the S-C afferents of field CA1 (***E***; *n* = 5/group). ***F***, Relationship of the peak amplitude of the fiber volley to the fEPSP slope (input/output curves) in the outer molecular layer of the DG with LPP stimulation in WT and CB~1~ KO mice: traces are averaged group responses after normalization of mean fEPSPs for individual slices to their peak amplitude. Group fEPSPs for WT and CB~1~ KO slices were indistinguishable. ***G***, LTP in the LPP was severely impaired in CB~1~ KO mice (*p* \< 0.0001; *n* = 10/group). ***H***, LTP did not differ between CB~1~ KOs and WTs in field CA1 (*p* = 0.89, *t*~(10)~ = 0.16: *n* = 6/group). All panels show results from field recordings (fEPSPs), except for the bar graph in ***C***, which shows the results of whole-cell, voltage-clamp recordings.](enu0041621010001){#F1}

Initial potentiation (during the first 2 min after HFS) in the field potential studies was not reliably affected by AM251 (veh, 98.1 ± 7.7%; AM251, 88.3 ± 10.0%; *p* \> 0.40). We conclude from this that CB~1~ receptors contribute to the stabilization, as opposed to the induction, of the potentiated state of LPP synapses. CB~1~-dependent potentiation appeared to be restricted to LPP synapses because AM251 had no effect on LTP at the adjacent MPP synapses (62.8 ± 6.9% for veh and 76.2 ± 8.5% for AM251; 5 µ[m]{.smallcaps} PTX in bath, both groups; [Fig. 1D](#F1){ref-type="fig"}) or for S-C projections to field CA1 (53.5 ± 6.6% for veh and 50.5 ± 11.2% for AM251; [Fig. 1E](#F1){ref-type="fig"}).

The obligatory role of CB~1~ in LPP-LTP was confirmed in experiments with hippocampal slices from CB~1~ knock-out (KO) mice ([@B21]). First, we tested whether the mutation changes basic response characteristics in the LPP using field recordings. The input/output relationship (number of axons stimulated---"fiber volley"---vs size of the evoked response) did not differ between WT and KO mice. The averaged fEPSP waveform for the KOs was also comparable to that in the WTs ([Fig. 1F](#F1){ref-type="fig"}). The mean time constant for the rising phase (rise tau) of the response (from start to 80% maximum) was 2.14 ± 0.44 ms for WTs and 1.94 ± 0.25 ms for CB~1~ KOs, and the time constant for the decay phase (decay tau) of the fEPSP was also not detectably different between genotypes (WT, 7.89 ± 1.46 ms; CB~1~ KO, 6.03 ± 2.62 ms). Despite the apparent normality of baseline evoked potentials, high-frequency stimulation failed to induce stable LTP at LPP synapses in CB~1~ KOs (WTs, 43.3 ± 3.1; CB~1~ KOs, 13.4 ± 2.9; *p* \< 0.0001; [Fig. 1G](#F1){ref-type="fig"}), although reliable potentiation was produced at S-C synapses in field CA1 in these mice (42.1 ± 6.2% for WTs and 43.7 ± 1.7% for KOs; [Fig. 1H](#F1){ref-type="fig"}). A recent study ([@B27]) reported CB~1~-dependent, heterosynaptic facilitation in field CA1. However, in agreement with earlier work ([@B24]; [@B109]; [@B62]; [@B1]), the induction of LTP in the present experiments did not increase responses to neighboring inputs in the S-C innervation of field CA1.

To identify the specific endocannabinoid involved in LTP at LPP contacts, we first tested the effects of agents that interrupt the enzyme-mediated degradation of either anandamide or 2-AG, the two major endocannabinoids in brain. JZL184 (1 µ[m]{.smallcaps}), an inhibitor of the 2-AG-degrading lipase MGL ([@B61]), which is localized to presynaptic elements in hippocampus ([@B30]), was verified to both suppress MGL activity ([Fig. 2A](#F2){ref-type="fig"}) and, as expected from this, to increase 2-AG levels ([Fig. 2B](#F2){ref-type="fig"}) in hippocampal slices. The infusion of JZL184, initiated 60 min before HFS, markedly enhanced LPP-LTP (43.2 ± 4.0% for veh; 78.3 ± 5.9% for JZL184; *p* = 0.001, *t* test, two-tailed). In contrast, LPP potentiation was not increased by URB597 (1 µ[m]{.smallcaps}; 42.3 ± 3.2% for veh; 34.1 ± 6.2% for URB597; *p* \> 0.25; *n* = 8 for veh, URB597; *n* = 5 for JZL184; [Fig. 2C](#F2){ref-type="fig"}), which inhibits the anandamide-degrading enzyme FAAH ([Fig. 2D](#F2){ref-type="fig"}). Thus, the magnitude of LPP potentiation was increased by a manipulation (JZL184) that increases 2-AG levels but not by one (URB597) that elevates anandamide.

![Lateral perforant path LTP depends upon the endocannabinoid 2-AG. ***A***, A 60 min treatment of acute hippocampal slices with JZL184 (1 µ[m]{.smallcaps}) reduced by 50% activity of the 2-AG degradative enzyme MGL (\*\*\**p* \< 0.001 vs veh, *t* test; *n* = 9 each). ***B***, Hippocampal slice levels of 2-AG were increased by JZL184 (1 µ[m]{.smallcaps}; \*\**p* \< 0.01; *n* = 10 for veh and JZL184) but decreased by perfusion of THL (10 µ[m]{.smallcaps}), an inhibitor of the 2-AG synthesizing enzyme DGL-α (\*\*\**p* \< 0.001; veh, *n* = 4; THL, *n* = 5). ***C***, As determined with fEPSP recordings, the magnitude of LPP potentiation was increased by JZL184 (1 µ[m]{.smallcaps}) but was not affected by URB597 (1 µ[m]{.smallcaps}), an inhibitor of FAAH. ***D***, URB597 (1 µ[m]{.smallcaps}) perfusion for 60 min reduced hippocampal slice FAAH activity (\*\*\**p* \< 0.001, *n* = 10 each). ***E***, LPP input/output curves were comparable for wild-type and MGL-overexpressing transgenics (MGL-tg) as were waveforms for averaged fEPSPs. ***F***, LPP-LTP was reduced in MGL-tg vs wild-type mice (*p* = 0.016; WT, *n* = 14; MGL-tg, *n* = 17). ***G***, ***H***, THL (10 µ[m]{.smallcaps}) perfused for 60 min significantly reduced LPP-LTP (***G***; *n* = 8/group) but not in S-C projections to field CA1 (***H***; *n* = 5/group). ***I***, WWL70, an inhibitor of the postsynaptic 2-AG degradative lipase ABHD6, had no effect on LPP-LTP; the modest effect of infusion on baseline responses reflects DMSO in the vehicle. ***J***, Infusion of the CB~1~ agonist WIN55,212-2 (5 µ[m]{.smallcaps}) for 1 h prior to, and overlapping, a brief high-frequency stimulation train (arrow) increased the magnitude of LTP relative to levels with veh treatment (*p* = 0.004; *n* = 6 for veh group, *n* = 7 for WIN group); WIN did not significantly influence baseline responses relative to those of the vehicle treatment group. In ***C*** and ***F--J***, the horizontal gray bar denotes the period of reagent perfusion; all electrophysiological analyses are from field recordings. Upward arrows indicate the time of LTP-inducing stimulation.](enu0041621010002){#F2}

We further tested the role of 2-AG in LPP-LTP using transgenic (tg) mice that selectively overexpress MGL in forebrain neurons; 2-AG levels in brain are reduced by ∼50% in these mice ([@B43]). Input/output curves for the LPP were comparable for MGL-tg versus WT mice (*p* \> 0.50, repeated measure (RM) ANOVA), and mean waveforms for the groups were superimposable ([Fig. 2E](#F2){ref-type="fig"}). Quantitative comparisons of mean rise and decay time constants confirmed that the elevated 2-AG levels in the mutants had no measurable effects on baseline excitatory transmission (rise tau: WT, 2.29 ± 0.22 ms; MGL-tg, 2.16 ± 0.24 ms; decay tau: WT, 10.66 ± 0.47 ms, MGL-tg, 10.78 ± 1.13 ms). However, LPP-LTP was significantly reduced in slices from MGL-tg mice (WT, 41.2 ± 6.8%; MGL-tg, 19.4 ± 4.7%; *p* = 0.016; [Fig. 2F](#F2){ref-type="fig"}). Consistent with these results, treatment with THL (10 µ[m]{.smallcaps}), an inhibitor of the 2-AG-synthetic enzyme diacylglycerol lipase-α (DGL-α), both substantially lowered 2-AG levels in hippocampal slices ([Fig. 2B](#F2){ref-type="fig"}) and significantly reduced LPP-LTP (veh, 47.4 ± 5.6%; THL, 22.9 ± 2.5%; *p* \< 0.002, two-tailed *t* test; [Fig. 2G](#F2){ref-type="fig"}). This treatment did not have reliable effects on TB-induced LTP of S-C projections in field CA1 (veh, 43.3 ± 4.0%; THL, 34.4 ± 6.6%; *p* \> 0.20; [Fig. 2H](#F2){ref-type="fig"}). Finally, inhibiting the postsynaptic 2-AG-hydrolyzing lipase, αβ-hydrolase domain-6 ([@B78]) with WWL70 (10 µ[m]{.smallcaps}) did not affect LPP-LTP (veh, 41.5 ± 2.9%; WWL70, 44.9 ± 4.5%; *n* = 6 each; [Fig. 2I](#F2){ref-type="fig"}).

Together, the above results obtained with agents or genetic manipulations that enhance or depress 2-AG signaling, support the conclusion that LTP in the LPP depends upon released 2-AG acting on CB~1~ receptors and mechanisms that do not entail suppression of GABAergic inhibition. These same studies did not detect the contributions of endocannabinoid or, more specifically, 2-AG involvement in activity-induced potentiation of the MPP or the S-C innervation of field CA1.

The threshold for LPP-LTP is markedly reduced by stimulation of CB~1~ receptors {#s4B}
-------------------------------------------------------------------------------

The above conclusion was further tested by asking whether direct stimulation of CB~1~ receptors promotes the induction of LTP in the LPP. We first established a stimulation paradigm (100 Hz for 200 ms) that is near the threshold for producing a measurable degree of stable potentiation. This stimulation protocol was then applied to slices in the presence of vehicle or the CB~1~ agonist WIN at a concentration (5 µ[m]{.smallcaps}) widely used in physiological and biochemical experiments ([@B95]); the effects of the agonist were evaluated with and without 100 µ[m]{.smallcaps} PTX present. There was no evident effect of WIN on baseline responses, but LPP potentiation was clearly enhanced: absent PTX, the mean percentage potentiation at 60 min in vehicle-treated slices was 12.3 ± 4.2% (*n* = 6), a value well below that obtained with full-length trains of high-frequency stimulation, and 35.3 ± 4.7% (*n* = 7) for the WIN treatment group (*p* = 0.004; [Fig. 2J](#F2){ref-type="fig"}). In the presence of PTX, the percentages of potentiation were 16.67 ± 5.87% (*n* = 6) and 43.43 ± 5.33% (*n* = 7) for vehicle and WIN treatment groups, respectively (*p* = 0.006). These results stand in marked contrast to those reported for S-C inputs of field CA1 that describe a clear inhibition of LTP induction with WIN infusion ([@B85]). The differential effects of WIN on stimulation-induced LTP constitute additional evidence for the marked difference in the substrates for potentiation between the LPP and field CA1 S-C systems, and support the conclusion that the triggering mechanisms for LTP in the former system, but not the latter system, involve endocannabinoid signaling.

LTP in the LPP is induced postsynaptically {#s4C}
------------------------------------------

2-AG signaling at glutamatergic synapses starts with mGluR5-dependent activation of DGL-α, which converts the membrane-bound 2-AG precursor 1-acyl-2-arachidonoyl-*sn*-glycerol into diffusible 2-AG ([@B5]; [@B41]). DGL-α requires calcium for activity and is localized to dendritic spines, where it forms a multimolecular complex with mGluR5 ([@B40]). Consistent with this model, we found that HFS-induced LPP-LTP is eliminated by voltage clamping granule cells with electrodes containing the calcium-buffering agent BAPTA, leading to intracellular infusion of the compound (percentage LTP: for veh, 148.0 ± 25.2%; for BAPTA, −14.4 ± 6.0%; *p* \< 0.0006, two-tailed *t* test; [Fig. 3A](#F3){ref-type="fig"}) or by bath perfusion with the NMDAR antagonist APV (percentage LTP: for veh, 47.2 ± 4.1%; for APV, 11.1 ± 4.6%; *p* \< 0.0004, two-tailed *t* test; [Fig. 3B](#F3){ref-type="fig"}). The mGluR5 antagonist MPEP (40 µ[m]{.smallcaps}) also markedly reduced LPP-LTP (veh, 44.3 ± 4.3%; MPEP, 15.3 ± 5.4%; *p* \< 0.0006; [Fig. 3C](#F3){ref-type="fig"}) without significantly affecting potentiation at MPP synapses (veh, 66.7 ± 6.4%; MPEP, 64.0 ± 5.1%; *p* = 0.18; [Fig. 3D](#F3){ref-type="fig"}) or in field CA1 (veh, 52.5 ± 7.1%; MPEP, 45.9 ± 3.6%; *p* = 0.27, *n* = 6/group; data not shown). It is interesting that postsynaptic calcium buffering or NMDAR antagonism blocked initial potentiation (∼2 min after induction), while MPEP (or AM251; see above) did not, even though all four manipulations blocked the production of stable LPP-LTP. These observations suggest that high-frequency stimulation generates rapid and delayed stages of potentiation in the LPP, with the former initiated by NMDAR-induced increases in postsynaptic calcium, and the latter by released 2-AG transmission. The initiation of the second, stable phase of response facilitation is clearly dependent upon first-stage events.

![Endocannabinoid-dependent LTP is blocked by buffering postsynaptic calcium and by glutamate receptor antagonists. ***A***, Whole-cell recordings of EPSCs elicited by single-pulse stimulation of the LPP were collected from granule cells with voltage-clamp electrodes containing veh (*n* = 7) or the calcium-chelating agent BAPTA (*n* = 10). Repetitive stimulation, with the membrane potential held at 0 mV, produced robust LTP in vehicle cases but no potentiation in BAPTA experiments. ***B***, Perfusion of NMDAR antagonist APV (100 µ[m]{.smallcaps}) blocked LPP-LTP in studies using field potentials (*p* \< 0.0004; *n* = 5/group). ***C***, ***D***, In field recording experiments, the mGluR5 antagonist MPEP (40 µ[m]{.smallcaps}) disrupted LPP-LTP (*p* \< 0.0006; *n* ≥ 9/group; ***C***) but had no effect on potentiation of the MPP (*p* \> 0.18, *t*~(10)~ = 1.5, *n* = 6/group; ***D***). PTX (10 µ[m]{.smallcaps}) was included in LPP experiments summarized in ***A--C***; horizontal bars indicate periods of reagent perfusion. Upward arrows in ***B--D*** indicate the application of HFS.](enu0041621010003){#F3}

It is noteworthy that the above manipulations did not affect the inward currents or depolarization of granule cell dendrites produced by high-frequency stimulation of the LPP. Past studies have shown that seconds-long depolarization of neurons via clamp electrodes depresses release from their excitatory and inhibitory afferents (depolarization-induced suppression of excitation or inhibition) via CB~1~ receptors ([@B14]). These effects are reported to be absent in both the LPP and MPP ([@B14]). It was therefore not possible to test how this form of endocannabinoid signaling is affected by the induction of LPP-LTP.

Evidence that LPP potentiation is expressed presynaptically {#s4D}
-----------------------------------------------------------

The LPP originates in the lateral entorhinal cortex and terminates in the outer molecular layer of the dentate gyrus ([@B111]; [@B108]; [@B2]). We found that in this field, as in many other brain regions ([@B45]; [@B71]; [@B65]; [@B107]), a substantial number of presynaptic nerve endings contain CB~1~ receptors: dual-immunolabeling STORM microscopy experiments revealed a high degree of overlap between immunoreactivity for CB~1~ and the axon terminal marker synaptophysin ([Fig. 4A](#F4){ref-type="fig"}). We quantified distances between centroids for CB~1~ and synaptophysin-immmunopositive (+) clusters in 36 sampling fields from seven rats and obtained a mean value of 90.1 ± 5.8 nm. The corresponding values for immunoreactivities for CB~1~ and PSD-95, which is concentrated in glutamatergic synapses, were 118.7 ± 3.0 nm (39 sampling fields; *p* \< 0.00001, *t* test). There was a significant interaction effect between distance and synaptic compartment (synaptophysin vs PSD-95) when comparing the frequency of CB~1~+ clusters at different distances (RM two-way ANOVA, *p* \< 0.005; [Fig. 4B](#F4){ref-type="fig"}). In addition, colocalization analysis showed that \>40% of synaptophysin+ clusters contained CB~1~ immunoreactivity (43.1 ± 4.9%). Since the excitatory entorhinal projections comprise \>80% of terminations in the DG molecular layer ([@B2]) these results confirm that CB~1~ receptors are localized in part to LPP terminals in this field.

![Presynaptic localization of CB~1~ receptors and expression of LPP-LTP. ***A***, Illustration of STORM images showing the overlapping distribution of CB~1~ (red) and synaptophysin (SYN; green) immunoreactivity in a terminal within the DG outer molecular layer when visualized as nanoscale localization points (left) and density blur of the same points showing the field of codistribution in yellow (right; the blur image is rotated 90°). ***B***, Histogram of nearest-neighbor distances between cluster centers of CB~1~ and either SYN^+^ or PSD-95^+^ elements. CB~1~^+^ clusters are more closely associated (\<30 μm) with SYN, indicating a preferential presynaptic localization (*n* = 7 rats each). ***C***, traces, Clamp recordings from a granule cell with paired-pulse stimulation of the LPP (40 ms interval between the pulses) before (black trace) and 30 min after (red trace) induction of LTP. Calibration: 200 pA, 20 ms. The graph shows that the magnitude of LPP PPF was reduced after potentiation (*p* = 0.0003, paired two-tailed *t* test, *n* = 10). ***D***, To assess NMDAR and AMPAR currents, EPSCs were measured with the membrane potential held at +40 mV before (black line) and after (blue line) the infusion of APV; DNQX was infused at the end of the recording session (green line). Calibration: 200 pA, 20 ms. ***E***, LTP did not decrease the NMDAR/AMPAR current ratio \[*p* \> 0.75; control (CON), *n* = 6; LTP, *n* = 7\]. ***F***, traces, Field recordings show LPP fEPSPs with paired-pulse stimulation of the LPP (40 ms between the pulses) before (black trace) and 30 min after (red trace) the induction of LTP. Bar graph shows that PPF of the fEPSP slope was reduced 30 min after inducing LPP-LTP relative to PPF during the pre-LTP baseline period (\*\*\*\**p* \< 0.00001, *n* = 22;). ***G***, In LPP field recordings, the change in PPF after the induction of LTP correlated with the magnitude of LTP.](enu0041621010004){#F4}

The imaging and pharmacological results suggest that LPP-LTP could be expressed through presynaptic changes. We used PPF ([@B75]) and whole-cell recordings of rat DG granule cells to test whether the effect is associated with changes in neurotransmitter release probability. Consistent with a presynaptic locus ([@B68]), potentiation was accompanied by a substantial reduction in PPF, as occurs when release is enhanced (*p* \< 0.0003, paired two-tailed *t* test; [Fig. 4C](#F4){ref-type="fig"}). Of interest, a recent study reported a smaller (\<10%) decrease in PPF after the induction of endocannabinoid-supported LTP in striatum ([@B18]). LTP was also accompanied by equivalent increases in the magnitude of synaptic currents gated by AMPA and NMDA receptor channels. For these studies, EPSCs were sampled with the membrane potential held at +40 mV before and after infusion of the NMDAR antagonist APV; the remaining (APV-insensitive) portion of the EPSC was due to AMPAR-gated currents, as confirmed with subsequent application of the AMPAR antagonist DNQX ([Fig. 4D](#F4){ref-type="fig"}). Subtracting the APV-insensitive response from the pre-APV EPSC yielded the NMDAR-mediated current. The ratio of the two components of the EPSC was then calculated and found to be comparable in control slices and those tested 30 min after induction of LPP-LTP (control, 1.82 ± 0.22; LTP, 1.90 ±0.16; *p* \> 0.75, *t* test; [Fig. 4E](#F4){ref-type="fig"}). Past studies in field CA1 showed that enhancing glutamate release from terminals produces similar increases in AMPAR- and NMDAR-mediated postsynaptic responses, whereas LTP selectively enhances AMPAR-gated currents ([@B46]; [@B75]). Accordingly, the results just described support the conclusion that, in contrast to CA1, LTP in the LPP is most likely due to presynaptic changes.

Paired-pulse facilitation results comparable to those found with voltage-clamp recordings were also obtained using extracellular field potentials (49.6 ± 2.9% pre-LTP; 34.5 ± 3.0% post-LTP; *p* \< 0.00001, paired *t* test; [Fig. 4F](#F4){ref-type="fig"}). A large number of slices was tested (*n* = 22) in order to determine whether the magnitude of fEPSP LTP was negatively correlated with the percentage change in PPF, as expected if the first variable is associated with the second. The results confirmed the prediction (percentage LTP vs percentage decrease in PPF: *r* = −0.638, *p* = 0.0014, Pearson test; [Fig. 4G](#F4){ref-type="fig"}).

It is of interest that previous work indicates that the mossy fiber output of the granule cells expresses a long-lasting form of release enhancement ([@B102]; [@B79]). However, LPP-LTP depends upon the concomitant activation of CB~1~ and NMDA receptors, both of which are dispensable for mossy fiber potentiation ([@B35]).

Presynaptic actin polymerization is required for LPP-LTP {#s4E}
--------------------------------------------------------

CB~1~ receptors engage G~i/~G~o~ proteins to initiate multiple signal transduction processes ([@B36]; [@B47]). While the effects on calcium channel activity have been a main focus of attention, results from studies of dissociated cells indicate that CB~1~ can promote cytoskeletal reorganization: CB~1~ receptors via G-proteins activate a large number of signaling cascades, including several small GTPases (RhoA, Rac, Rap) that engage, among other targets, actin regulatory elements ([@B34]; [@B80]; [@B91]; [@B66]; [@B81]) and can effect actin-dependent changes in release ([@B67]). These observations suggested the possibility that cytoskeletal changes underlie enhanced glutamate release with LPP-LTP.

We used Lat-A, which sequesters monomeric G-actin leading to the dissolution of recently formed, "treadmilling" actin polymers ([@B55]), to test the broad hypothesis described above. Because Lat-A interferes with cytoskeletal processes required for postsynaptic LTP ([@B52]; [@B89]), we compared the effects of intracellular infusion of Lat-A to block postsynaptic actin dynamics with those of extracellular application, which acts both presynaptically and postsynaptically. Including 400 n[m]{.smallcaps} Lat-A in the clamp electrode, leading to intracellular infusion of the toxin, depressed LTP in CA1 pyramidal cells by \>50% (veh, 125.8 ± 19.5%; Lat-A, 56.9 ± 16.5%; *p* \< 0.026) without disturbing baseline physiology ([Fig. 5A](#F5){ref-type="fig"}). This result corroborates prior reports that LTP in field CA1 depends on postsynaptic actin polymerization; it also provides evidence that intracellular infusion reaches the secondary and tertiary branches on which synaptic modifications occur. In contrast, clamp electrode infusion of the same concentration of Lat-A into granule cells had no effect on the magnitude of LPP-LTP (control, 141.7 ± 24.0% LTP; Lat-A, 145.6 ± 23.8%; [Fig. 5B](#F5){ref-type="fig"}). However, extracellular applications of Lat-A significantly reduced LPP potentiation (veh 36.9 ± 3.4%; Lat-A, 16.7 ± 2.1%; *p* = 0.0002; [Fig. 5C](#F5){ref-type="fig"}). These results indicate that the expression of endocannabinoid-dependent LTP in the LPP requires adjustments to the presynaptic actin cytoskeleton.

![Presynaptic cytoskeletal changes are required for LPP-LTP. ***A***, Whole-cell, voltage-clamp recordings from CA1 pyramidal cells using electrodes containing Lat-A (400 nM) or veh. Baseline EPSCs were obtained at 3/min for 10 min and then repetitive stimulation applied with membrane potential held at 0 mV. Intracellular Lat-A infusion markedly reduced field CA1 LTP (*p* \< 0.026, *n* ≥ 6/group). ***B***, Whole-cell recordings show that intracellular Lat-A infusion into DG granule cells had no effect on LTP elicited by LPP stimulation (*n* = 7/group). ***C***, Field EPSP recordings of LPP responses show that extracellular Lat-A perfusion (500 n[m]{.smallcaps}, at horizontal bar) disrupted the stabilization of LPP-LTP (fEPSP recordings; *p* = 0.0002, *n* = 8/group).](enu0041621010005){#F5}

Contributions of endocannabinoid-dependent LPP-LTP to memory {#s4F}
------------------------------------------------------------

The LPP serves as the gateway for olfactory and associational information from piriform and polymodal regions of neocortex, respectively ([@B37]; [@B10]; [@B112]). Consonant with this, past studies showed that lesions of the LPP severely impair the formation of memory for simultaneous (but not serial) two-odor discriminations ([@B101]; [@B82]). We tested whether pharmacological manipulation of 2-AG signaling disturbs this form of odor learning, as would be expected if LPP-LTP were involved. Rats were trained on a series of simultaneous two-odor discriminations, each involving a different odor pair (one pair presented in 10 trials/d; [Fig. 6A](#F6){ref-type="fig"}). They were then tested for their ability to learn a new odor pair with the 10 training trials initiated 1 h after the injection of vehicle or AM251 (1 mg/kg, i.p.): the percentage of correct responses was assessed for the first five trials during this final discrimination training (day 1) and during retention testing on day 5 (no drug) trials 24 h later (day 2). Vehicle-treated rats showed clear retention, with scores on day 2 being comparable to those previously described for this paradigm ([@B58]; [@B69]), whereas the AM251 group did not ([Fig. 6B](#F6){ref-type="fig"}, left; *p* = 0.001, two-tailed *t* test). Because CB~1~ has been implicated in processing olfactory signals ([@B100]), we repeated the comparisons using only those rats that exhibited strong evidence for learning on day 1 (≥80% correct on trials 6--10). Again, we found a marked difference in retention between control and AM251-treated rats (*p* = 0.018; [Fig. 6B](#F6){ref-type="fig"}, right), suggesting that CB~1~ blockade impaired the formation of long-term memory in rats that had initially acquired the odor discrimination.

![Odor learning engages, and depends upon, elements of LPP-LTP. ***A***, Rats were trained to find rewards in two small cups and then were given a series of novel two-odor discriminations with experiments conducted on the final discrimination. ***B***, Percentage of correct responses for the first 5 of 10 trials on the final discrimination (d1, day 1) and then on retention trials administered 24 h later (d2, day 2; no drug present). ***B***, Left, Rats injected with veh before training (open bars) had a high percentage of correct scores on d2, while rats injected with AM251 (1 mg/kg; filled bars) did not (*p* = 0.001, *t* test; *n* = 10/group). Right, Rats were given only six discrimination trials on d1 and then were retested for retention 24 h later: animals given the MGL inhibitor JZL184 (16 mg/kg) before d1 training had a higher percentage of correct scores on d2 than did vehicle-treated rats (*p* = 0.008; *n* = 10/group). ***C***, Rats in the experimental (learn) group (*n* = 15) were trained (10 trials) on odor cues, and then the DG was assayed for levels of 2-AG and the related lipid OEA; values were normalized within animals to those from auditory cortex or field CA1 (used as comparison regions in separate cohorts) and then were converted to *z*-scores (the number of SDs from the control group mean for each individual from each group). Control rats (*n* = 13) were transported to, but not placed in, the testing environment. DG 2-AG levels were significantly greater in the trained ("learn") group than in control rats (*p* = 0.028, unpaired, two-tailed *t* test); OEA levels were not different between groups.](enu0041621010006){#F6}

As described above, elevating 2-AG levels with the MGL inhibitor JZL184 markedly enhanced LTP in the LPP ([Fig. 2C](#F2){ref-type="fig"}). We tested whether the compound (16 mg/kg) given 30 min before odor discrimination training also strengthens the encoding of long-term memory. Six training trials on day 1 were not sufficient to produce high retention scores in tests administered 24 h later for vehicle-treated rats but resulted in clear evidence for long-term memory in the JZL184 treatment group (*p* = 0.008; [Fig. 6B](#F6){ref-type="fig"}, right).

The above results suggest that LPP-dependent learning initiates 2-AG signaling in the DG. To test this idea, we subjected rats to the day 1, 10 trial training protocol, snap froze their brains, and measured 2-AG content in lipid extracts using liquid chromatography/mass spectrometry ([@B42]). Dentate gyrus 2-AG levels were significantly elevated in trained rats, compared with untrained controls (*p* = 0.028, *t* test; [Fig. 6C](#F6){ref-type="fig"}). Anandamide levels were undetectable in both trained and control rats, and no group differences were evident for other endocannabinoid-related lipids, such as oleoylethanolamide ([Fig. 6C](#F6){ref-type="fig"}).

Discussion {#s5}
==========

In many central synapses, dendritic spine-derived 2-AG engages CB~1~ receptors on axon terminals to cause short-term or long-term depression of neurotransmitter release ([@B44]; [@B12]). The present results extend this standard model by showing that 2-AG-dependent retrograde signaling mediates synaptic potentiation, rather than inhibition, at the glutamatergic synapses formed by the LPP with granule cells of the DG. As schematized in [Figure 7](#F7){ref-type="fig"}, the results indicate that this form of endocannabinoid-mediated LTP is initiated postsynaptically through a mechanism that requires the activation of mGluR5 and NMDA receptors along with increases in postsynaptic calcium, to influence DGL-α and the production of 2-AG, but is expressed in axon terminals via a long-lasting increase in glutamate release. Experiments with a selective toxin that prevents actin filament assembly (latrunculin A) provided evidence that the latter effect involves reorganization of the actin cytoskeleton in LPP terminals. Activation of CB~1~ receptors by 2-AG plays an obligatory, initiating role in shifting the boutons into the potentiated state.

![Schematic illustration of the proposed substrates for LTP in the LPP. The present evidence, and results described in the literature, suggest that the illustrated events are critical for the production of LPP-LTP. Glutamate (green triangles) released with brief bursts of high-frequency afferent stimulation activates NMDA- and mGluR5-type glutamate receptors and increases postsynaptic calcium content; these events engage the 2-AG synthesizing enzyme DGL-α. 2-AG produced postsynaptically then diffuses across the synapse and binds to CB~1~ receptors on LPP terminals, thereby initiating signaling via small GTPases and the assembly of latrunculin-sensitive actin filaments. The resultant reorganization of the terminal actin cytoskeleton enhances evoked transmitter release.](enu0041621010007){#F7}

Using pharmacological and genetic manipulation of 2-AG content and CB~1~ receptor function, and electrophysiological analysis of hippocampal slices, we found no evidence for a 2-AG contribution to LTP at sites outside the LPP (i.e., MPP, CA1), although earlier studies have described both positive and negative effects of CB~1~-related compounds on induction in other systems (see Introduction). The present results were obtained with near-threshold parameters for inducing robust and stable LTP, and it is possible that a modulatory influence of endocannabinoids emerges with different conditions at various locations in hippocampus. Pertinent to this, a recent report ([@B113]) described a presynaptic, endocannabinoid-dependent form of LTP in the S-C afferents of field CA1 elicited with paired stimulation of S-C and perforant path axons. Unlike the case for the LPP described here, this paired stimulation CA1 effect was dependent upon GABAergic transmission. Another group identified a novel, heterosynaptic form of presynaptic LTP in the S-C system triggered by 2-AG acting on astrocytes ([@B77]; [@B27]). Given that LTP production in the S-C projections by minimal TB stimulation ([@B57]; [@B56]) is synapse specific, intact in CB~1~ knockouts ([Fig. 1](#F1){ref-type="fig"}) and expressed postsynaptically ([@B75]; [@B68]; [@B48]; [@B29]), these recent findings raise the intriguing possibility that S-C synapses have a normally unused capacity to express a form of potentiation of a kind described here for the LPP. Possibly related to this, the present studies compared LPP results obtained from whole-cell recording with those from the less invasive field recording. It may be useful to use similar comparisons in future studies of other connections as clamp electrodes are known to affect channel operations and receptor kinetics ([@B72]; [@B99]; [@B59]).

Further differentiation of the LTP-related role of endocannabinoids in the LPP versus the S-C system was obtained using the CB~1~ agonist WIN. Past studies showed that WIN treatment potently impairs S-C LTP ([@B85]), whereas we found that WIN enhances potentiation in the LPP. It is noteworthy that fast gamma activity (65-130 Hz) occurs in the entorhinal cortex of behaving animals and extends across multiple cycles of the theta rhythm ([@B17]); thus ∼100 Hz activity (as used for the production of LPP-LTP) is present for hundreds of milliseconds in the perforant path. The near-threshold LPP stimulation used in the WIN treatment studies is not greatly different from this pattern.

The failure to detect endocannabinoid-initiated, presynaptic LTP in MPP terminals, which innervate the granule cells in the field immediately adjacent to the LPP, was somewhat surprising. Little is known about the substrates for LTP expression in the MPP, although the available evidence points to postsynaptic modifications ([@B8]; [@B33]). As noted, the mossy fibers generated by the granule cells are reported to be unresponsive to agents that affect CB~1~ receptors ([@B35]). These findings reinforce the conclusion that conventional stimulation protocols do not elicit the type of LTP found in the LPP at other sites in hippocampus.

An intriguing feature of potentiation in the LPP is that the magnitude of the effect, as recorded under control conditions, is much less than maximal: the inhibition of the 2-AG hydrolyzing enzyme MGL nearly doubled the magnitude of LPP potentiation. Moreover, in comparison with measures in field recording experiments, LPP-LTP was substantially larger in voltage-clamp experiments in which induction occurs under circumstances that maximize the opening of NMDAR channels. This pattern of results suggests that in response to threshold levels of stimulation some individual LPP terminals do not fully potentiate or that a large subpopulation of activated contacts fails to shift into the potentiated state. Notably, the difference between extracellular versus clamp recording with regard to LTP-related decreases in PPF were not comparable to the marked separation in the magnitude of LTP. This argues against the possibility that the large-amplitude LPP-LTP observed in whole-cell preparations was due to greater release from individual terminals in comparison to that in field potential studies. Instead, the results from MGL inhibition and clamp recording experiments point to the hypothesis that NMDAR activation at some LPP contacts was not sufficient to generate the 2-AG signaling that triggers the presynaptic expression of potentiation in this system. This idea finds precedent in studies of postsynaptic LTP in field CA1, where approximately half the synapses were shown to have high plasticity thresholds ([@B54]; [@B64]).

Studies of postsynaptic LTP have also provided considerable information about the mechanisms that express and stabilize the potentiated state. These include membrane trophic (BDNF; [@B51]; [@B83]), steroid (estradiol; [@B53]), and adhesion ([@B52]; [@B7]; [@B4]) receptors that engage multiple actin signaling pathways that reorganize the subsynaptic cytoskeleton ([@B96]; [@B64]; [@B92]). Given the present evidence that LPP-LTP depends on presynaptic actin filament assembly, it is conceivable that comparable events within LPP axon terminals mediate the production of this endocannabinoid-dependent potentiation. Pertinent to this, recent studies have described novel endocannabinoid signaling in pancreatic cells ([@B67]) and neuronal cell lines ([@B22]; [@B19]; [@B91]; [@B66]; [@B81]) that involves GTPase and other actin regulatory cascades, interactions with surface adhesion receptors belonging to the integrin family, and cytoskeletal reorganization. There is an extensive body of work showing that actin networks in axon terminals influence the docking of transmitter vesicles and, thus, levels of evoked release ([@B93]; [@B84]). It will be of considerable interest in future work to test whether the assays and manipulations used to identify cytoskeletal substrates of postsynaptic LTP detect comparable presynaptic events associated with endocannabinoid-dependent LPP-LTP. Such studies would require the broad range of technologies used in the analysis of stabilization mechanisms in field CA1.

The results of several studies indicate that endocannabinoids are involved in memory formation ([@B31]; [@B87]; [@B104]; [@B3]; [@B28]; [@B94]), and we confirmed the prediction from LTP experiments that manipulations of 2-AG signaling that were shown here to suppress or enhance LPP-LTP produce corresponding effects on LPP-dependent learning. Specifically, we found that these manipulations had predicted effects on odor discrimination learning. These behavioral results were obtained using peripheral injections of the compounds (AM251, JZL184), and thus it is possible that global effects could have contributed to the observed changes in memory encoding. Arguing against this is the observation that drug-treated animals acquired the discrimination during day 1 testing, indicating that cue processing was intact. More detailed analyses will be possible if further slice studies identify actin signaling events required for the stabilization of LPP-LTP, and if these markers prove applicable to behavioral studies (as was the case for field CA1; [@B26]; [@B13]; [@B97]). Local applications of CB~1~ and 2-AG-related compounds could then be used to target the DG to further test the role of endocannabinoids, and LPP-LTP, in memory encoding.

A substantial literature indicates that conventional, postsynaptic LTP, as best characterized in field CA1, provides a substrate for several types of memory ([@B74]; [@B98]; [@B76]; [@B92]), and so the question arises, why is this type of plasticity not used by the LPP? And, related to this, what is the functional significance of utilizing distinct forms of plasticity in the two cortical inputs to the dentate gyrus? One possibility relates to the strong likelihood that the two afferents, MPP and LPP, convey different, simultaneously present categories of information. Recent behavioral and imaging studies led to the hypothesis that the MPP and LPP play complementary roles in the encoding of the "what," "when," and "where" components of episodic memories, with the MPP related to spatial relationships between cues (where) and the LPP to cue identity (what; [@B88]). Individual granule cells are innervated by both systems and then project to the pyramidal cells of the hippocampus proper where a third dimension---temporal order---is added to the memory of a cue sequence ([@B25]). It is possible that granule cells separate the two types of information they receive by encoding one and then the other on successive steps in a cycle, a process that would be facilitated by introducing a specialized form of plasticity at only one of the inputs. Pertinent to this, the dentate gyrus receives a small but functionally potent cholinergic projection originating in the medial septum/diagonal bands complex (MS/DBB; [@B2]). Released acetylcholine both stimulates the synthesis of 2-AG ([@B114]) and depresses glutamate release from the MPP via a CB~1~-dependent mechanism ([@B16]). It is therefore possible that elevated activity in the cholinergic inputs to the dentate gyrus could at the same time promote LTP in the LPP, via mechanisms described here, while disrupting potentiation in the MPP. In this sense, the MS/DBB would act as a gatekeeper that allows first one and then a second type of information to be encoded on the same neurons.
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Synthesis {#s6}
=========

The decision was a result of the Reviewing Editor Howard Eichenbaum and the peer reviewers coming together and discussing their recommendations until a consensus was reached. A fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision is listed below. The following reviewers agreed to reveal their identity: Pablo Castillo, Vijayalakshmi Santhakumar

While the authors have addressed some of the concerns in the original submission, and one reviewer is satisfied, the other reviewer has some remaining concerns that must be addressed.

Reviewer \#1:

In this revised manuscript, the authors have addressed some of my previous concerns. Specifically, they have modified the text and performed one of the several experiments I requested. Important points remain unanswered, and there are still a number of loose ends regarding the mechanism underlying ecLTP.

1\) In my previous report I requested: \"The authors must test the prediction that a CB1 agonist potentiates LPP (but not MPP) synaptic transmission, in a FAK signaling-dependent but GABAa receptor-independent manner.\" The idea here is to test whether activation of CB1 receptors is sufficient to mimic ecLTP. The authors decided not to perform this simple experiment. Instead, they report that the CB1 receptor agonist WIN facilitates induction by some unknown mechanism. Moreover, it is unclear whether inhibition was intact in the new experiments reported in Fig 2J. In lines 353/354, they also claim that WIN had no evident effect on baseline responses. However, it appears that WIN actually increases synaptic transmission at the end of the bath application, right before the LTP induction protocol (Fig 2J). They should keep recording baseline transmission for two hours in the absence of the LTP induction protocol. Regarding the mechanism of CB1 receptor-mediated potentiation, the authors propose that FAK signaling could be involved but decided not to explore this possibility experimentally. It is unclear why they are reluctant to test FAK inhibitors.

2\) \"The presynaptic localization of CB1 receptors in LPP terminals is not convincing.\" Additional evidence that CB1 receptors colocalize with some specific marker of glutamatergic terminals is required (see Uchigashima et al, 2011, J. Neurosci 31:7700 -7714). In the absence of such marker(s), or LPP tracers as well suggested by reviewer \#1, the results reported in Fig 4AB are not conclusive and should be removed. How do we know that the image in Fig 4A is not from a GABAergic terminal? The authors should show STORM images of CB1/PSD95 distribution as in 4A.

3\) Remove from the text (and figure legend) all suggestions that ecLTP contributes to memory. The study does not provide any direct evidence in support of this link. The results are, at best, correlational.

4\) The authors must provide a model (cartoon) of how ecLTP works. For example, the model should indicate whether NMDARs and mGluRs are pre or postsynaptic, how they are activated and how they engage endocannabinoid signaling at LPP-DGC synapses.

5\) Given that LPP-LTP was blocked by postsynaptic BAPTA and d-APV (Fig. 3A,B), can the authors discard the contribution of a Hebbian component? Is LPP-LTP abolished in CB1 KO mice? Is it impaired by MPEP and extracellular Lat-A? These points have not been addressed in the revised manuscript. The authors only indicate that SR141716A dramatically reduced HFS-induced LTP (Fig 1A, inset). They assume, but have not actually tested, whether HFS-induced LTP and pairing protocol-induced LTP are mechanistically identical.

6\) To my question \"Why vehicle applications increase baseline transmission in DG but not CA1?\", the authors responded: \"The only case in which vehicle infusion produced an evident increase in baseline involved the compound WWL70\". However, clear changes in baseline can also be observed in Fig. 1A, 1B, 2C, 2G, making the interpretation and quantification of the results rather difficult.

7\) Re: presynaptic expression of ecLTP, the authors may want to add some qualifier throughout the text and modify their conclusions as follows \"LTP in the LPP is \*likely\* expressed presynaptically\".

8\) If the authors want to claim that ecLTP is input-specific -i.e. expressed at LPP but not MPP synapses- they should test whether the exact induction protocols that trigger ecLTP at LPP synapses do not induce ecLTP at MPP synapses.

9\) Fig 1A inset: show time course plot as for all other LTP plots in this figure.
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